The NRG1/ErbB4 receptor signaling pathway plays a critical role in the regulation of cardiovascular development, vascular biology, and cardiac injury. This review provides an overview of the NRG/ErbB receptor signaling pathway and its involvement in the regulation of cardiac development, vascular biology, and cardiac injury. We discuss the regulation of NRG on vascular biology and vascular regeneration, the endogenous activation of NRG1/ErbB receptor signaling pathway in alleviating myocardial ischemic injury, and the potential therapeutic value of NRG1 on myocardial injury and heart failure.

Anbiao Wang, Pengfei Li, Xiaoshu Li, Runqian Sui, Zi Jie. Research Progress of NRG1/ErbB4 Receptor Signaling Pathway in the Cardiovascular Field. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 7: 63-69. https://doi.org/10.25236/IJFM.2023.050710.

[1] Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 2015 Apr 8; 10(Suppl 1):1-9. doi: 10.4137/BMI.S20061. PMID: 25922571; PMCID: PMC4395047.

[2] Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-516.

[3] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-1134.

[4] Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-354.

[5] Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79:34-74.

[6] Lemmens K, Keulenaer K D A G W D. Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease Implications for Therapy of Heart Failure[J]. Circulation, 2007, 116(8):954–960.

[7] Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009; 138(2):257-270. doi: 10.1016/j.cell.2009.04.060

[8] Stanton LW, Garrity DM, Damm D, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res. 2000; 86(9):939-945. doi: 10.1161/01.res.86.9.939

[9] Fukazawa R, Miller TA, Kuramochi Y, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 2003; 35(12):1473-1479. doi: 10.1016/s0022-2828(03)00298-6

[10] Gude N, Sussman MA. Investigating neuregulin and ERBB receptor signaling in regeneration. Cell Mol Life Sci. 2012; 69(15):2273-2282. doi: 10.1007/s00018-012-0942-4

[11] Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009 Jun 12; 138(6):257-70.

[12] Chen M, Liu Y, Hao G, Chen Y, Wu D, Gao P, et al. Neuregulin-1β induces cardiomyocyte hypertrophy through erbB4 receptor tyrosine kinase activation. Mol Cell Biochem. 2013 Jan; 372(1-2):27-35.a

[13] Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 2010 Jul; 61(1):1-18.

[14] Lei M, Jones SA, Liu J, Lancaster MK, Fung SS, Dobrzynski H, et al. Requirement of neuronal- and cardiac-type sodium channels for murine sinoatrial node pacemaking. J Physiol. 2004 Oct 15; 559(Pt 2):835-48.

[15] Lei M, Zhang H, Grace AA, Huang CL. SCN5A and sinoatrial node pacemaker function. Cardiovasc Res. 2007 Jan 1; 74(1):356-65.

[16] Liu X, Chen J, Lu Y, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006; 48(7):1438-1447.

[17] Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010; 55(19):1907-1914.

[18] Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011; 13(1):83-92.

[19] Chan J, Jacquet L, Lowes BD, et al. A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of neuregulin-1 in patients with chronic heart failure. J Card Fail. 2012; 18(9):672-681.

[20] Jabbour A, Hayward CS, Keogh AM, et al. Efficacy and safety of intravenous and subcutaneous administration of biosimilar filgrastim (Hospira Nivestim) compared with reference filgrastim (Neupogen) for peripheral blood stem cell mobilisation using G-CSF in patients with lymphoma or multiple myeloma: a randomised, crossover phase 3 study. Lancet Haematol. 2015; 2(10):e454-e463.

[21] Polizzotti BD, Ganapathy B, Walsh S, et al. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci Transl Med. 2015; 7(281):281ra45.

[22] Liu H, Liu Y, Cheng L, et al. The therapeutic efficacy of neuregulin-1 (NRG-1) on improving ventricular remodeling and cardiac function in heart failure: a meta-analysis. Medicine (Baltimore). 2017; 96(29):e7573.

[23] Zhang Y., Liao M., Dufau M. L., & Duan C. (2011). NRg1 stimulates glucose uptake in the absence of insulin and GLUT4 translocation. Endocrinology, 152(11), 3909-3919.

[24] Wang L., Huang X., Zhu Y., Zhang J., Zhou X., & Luo X. (2019). NRG1 protects against myocardial fibrosis in mice via the inhibition of the TGF-β1/Smad signaling pathway. International journal of molecular medicine, 44(5), 1831-1842.

[25] Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. Circ Res. 2012; 111(10):1376-1385. doi:10.1161/CIRCRESAHA.112.279051

[26] Liu X, Zhao Y, Gao J, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006; 48(7):1438-1447. doi:10.1016/j.jacc.2006.06.062

[27] Polizzotti BD, Ganapathy B, Walsh S, Choudhury S, Ammanamanchi N, Bennett DG. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci Transl Med. 2015; 7(281):281ra45. doi:10.1126/scitranslmed.aaa5171

[28] Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010; 55(18):1907-1914. doi:10.1016/j.jacc.2009.12.045

[29] Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998; 273(19):10261-10269. doi:10.1074/jbc.273.19.11936

[30] Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009; 138(2):257-270. doi:10.1016/j.cell.2009.04.060

[31] Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol. 2011; 300(3):H931-H942. doi:10.1152/ajpheart.00341.2010

[32] Liu Y, et al. Recombinant neuregulin-1 protects against myocardial injury in a rat model of ischemia-reperfusion. Can J Physiol Pharmacol. 2019; 97(5):393-401. doi: 10.1139/cjpp-2018-0458

[33] Huang Y, et al. Neuregulin-1 attenuates myocardial ischemia-reperfusion injury by inhibiting the inflammatory response and apoptosis in mice. Exp Ther Med. 2019; 17(1):231-238. doi: 10.3892/etm.2018.6969

[34] Lemmens K, et al. Neuregulin-1 and its role in the modulation of myocardial function: from bench to bedside. Acta Cardiol. 2010; 65(5):481-490. doi: 10.2143/AC.65.5.2051429

[35] Galindo CL, et al. Therapeutic potential of NRG1, a member of the EGF family of growth factors, in neurological and neuropsychiatric disorders. Neurotherapeutics. 2014; 11(4):823-835. doi: 10.1007/s13311-014-0302-1

[36] Jabbour A, et al. Neuregulin in cardiovascular disease and angiogenesis. Curr Vasc Pharmacol. 2011; 9(6):687-696. doi: 10.2174/157016111796642849

[37] Gao R, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010; 55(18):1907-1914. 

[38] Huang Z, Chen X, Chen D, et al. Intramyocardial Injection of Neuregulin-1β Promotes Endogenous Cardiac Repair and Survival in Infarcted Rats. Cell Physiol Biochem. 2016; 39(1):229-238. doi:10.1159/000445616

[39] Gao R, Zhang J, Cheng L, et al. A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients with Chronic Heart Failure. J Am Coll Cardiol. 2010; 55(18):1907-1914. doi:10.1016/j.jacc.2010.01.035

[40] Bersellini-Farinotti A, Ceconi C, Fedele S, et al. Neuregulin-1 supplementation for heart failure: a dose-escalation study. Eur J Heart Fail. 2020; 22(1):41-50. doi:10.1002/ejhf.1684

[41] Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med. 2012; 367(22):2150-2153. doi:10.1056/NEJMp1211776

[42] Gude NA, Emmanuel G, Wu W, et al. Activation of Notch-mediated protective signaling in the myocardium. Circ Res. 2008; 102(9):1025-1035. doi:10.1161/CIRCRESAHA.107.168546

[43] Liu X, Gu X, Li Z, et al. Neuregulin-1/ErbB signaling in cardiac development and diseases. Front Physiol. 2016; 7:230. doi: 10.3389/fphys. 2016.00230.

[44] Chen MM, Ashley EA, Deng DX, et al. Navigating the future of cardiovascular drug development—right targets, wrong patients, or both? Nat Rev Cardiol. 2017; 14(3):135-146.

[45] Zhang Y, Huang L, Zhang J, et al. A novel mechanism of neuregulin action promoting cardiomyocyte proliferation and survival. J Cell Mol Med. 2019; 23(10):6854-6864.